New drugs and combinations for the treatment of soft-tissue sarcoma: a review

References

• JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin2011612699021296855
   PubMed Web of Science ®Google Scholar
• StojadinovicALeungDHHoosAJaquesDPLewisJJBrennanMFAnalysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomasAnn Surg2002235342443411882765
   PubMed Web of Science ®Google Scholar
• O’SullivanBDavisAMTurcotteRPreoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trialLancet200235993252235224112103287
   PubMed Web of Science ®Google Scholar
• [No authors listed]Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis CollaborationLancet19973509092164716549400508
   PubMed Web of Science ®Google Scholar
• PervaizNColterjohnNFarrokhyarFTozerRFigueredoAGhertMA systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcomaCancer2008113357358118521899
   PubMed Web of Science ®Google Scholar
• WollPJVan GlabbekeMHohenbergerPAdjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): interim analysis of a randomised phase III trialJ Clin Oncol200725Suppl 1810008
   Web of Science ®Google Scholar
• O’ConnorJMChacónMPetracciFEChacónRDAdjuvant chemotherapy in soft tissue sarcoma (STS): a meta-analysis of published dataJ Clin Oncol200826 Suppl10526
   Google Scholar
• BramwellVRouesseJStewardWAdjuvant CYVADIC chemotherapy for adult soft tissue sarcoma – reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupJ Clin Oncol1994126113711498201375
   PubMed Web of Science ®Google Scholar
• Le CesneAVan GlabbekeMWollPJThe end of adjuvant chemotherapy (adCT) era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma (STS): pooled analysis of the two STBSG-EORTC phase III clinical trialsJ Clin Oncol200826 Suppl10525
   Web of Science ®Google Scholar
• FerrariAGronchiACasanovaMSynovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institutionCancer2004101362763415274077
   PubMed Web of Science ®Google Scholar
• EilberFCEilberFREckardtJThe impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcomaAnn Surg20042404686695 discussion 695–68715383796
   PubMed Web of Science ®Google Scholar
• VerweijJMouridsenHTNielssenOSThe present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of viewCrit Rev Oncol Hematol19952031932018748009
   PubMed Web of Science ®Google Scholar
• HensleyMLMakiRVenkatramanEGemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trialJ Clin Oncol200220122824283112065559
   PubMed Web of Science ®Google Scholar
• HensleyMLBlessingJADegeestKAbulafiaORosePGHomesleyHDFixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II studyGynecol Oncol2008109332332818394689
   PubMed Web of Science ®Google Scholar
• HensleyMLBlessingJAMannelRRosePGFixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trialGynecol Oncol2008109332933418534250
   PubMed Web of Science ®Google Scholar
• MakiRGWathenJKPatelSRRandomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]J Clin Oncol200725192755276317602081
   PubMed Web of Science ®Google Scholar
• BayJORay-CoquardIFayetteJDocetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysisInt J Cancer2006119370671116496406
   PubMed Web of Science ®Google Scholar
• SleijferSOualiMvan GlabbekeMPrognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)Eur J Cancer2010461728319853437
   PubMed Web of Science ®Google Scholar
• FuryMGAntonescuCRVan ZeeKJBrennanMFMakiRGA 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapyCancer J200511324124716053668
   PubMed Web of Science ®Google Scholar
• ScurrMHistology-driven chemotherapy in soft tissue sarcomasCurr Treat Options Oncol2011121324521359911
   PubMed Web of Science ®Google Scholar
• AntmanKCrowleyJBalcerzakSPAn intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomasJ Clin Oncol1993117127612858315425
   PubMed Web of Science ®Google Scholar
• BramwellVHAndersonDCharetteMLDoxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guidelineSarcoma20004310311218521288
   PubMedGoogle Scholar
• JelicSKovcinVMilanovicNRandomised study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcomaEur J Cancer19973322202259135492
   PubMed Web of Science ®Google Scholar
• Le CesneAJudsonICrowtherDRandomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma GroupJ Clin Oncol200018142676268410894866
   PubMed Web of Science ®Google Scholar
• HartmannJTOechsleKHuoberJAn open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcomaInvest New Drugs200624324925316133789
   PubMed Web of Science ®Google Scholar
• PazdurRSamsonMKBakerLHFludarabine phosphate. Phase II evaluation in advanced soft-tissue sarcomasAm J Clin Oncol19871043413432441592
   PubMed Web of Science ®Google Scholar
• ReichardtPOechsleKPinkDAn open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcomaInvest New Drugs200321448148614586217
   PubMed Web of Science ®Google Scholar
• RosePGBlessingJASoperJTBarterJFProlonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group studyGynecol Oncol19987022672719740703
   PubMed Web of Science ®Google Scholar
• WollPJJudsonILeeSMTemozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma GroupEur J Cancer199935341041210448291
   PubMed Web of Science ®Google Scholar
• Van GlabbekeMVerweijJJudsonINielsenOSProgression-free rate as the principal end-point for phase II trials in soft-tissue sarcomasEur J Cancer200238454354911872347
   PubMed Web of Science ®Google Scholar
• David-CordonnierMHGajateCOlmeaODNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedinChem Biol200512111201121016298299
   PubMedGoogle Scholar
• TakebayashiYPourquierPZimonjicDBAntiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repairNat Med20017896196611479630
   PubMed Web of Science ®Google Scholar
• FriedmanDHuZKolbEAGorfajnBScottoKWEcteinascidin- 743 inhibits activated but not constitutive transcriptionCancer Res200262123377338112067978
   PubMed Web of Science ®Google Scholar
• TakebayashiYGoldwasserFUrasakiYKohlhagenGPommierYEcteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expressionClin Cancer Res20017118519111205907
   PubMed Web of Science ®Google Scholar
• HerreroABMartin-CastellanosCMarcoEGagoFMorenoSCross- talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedinCancer Res200666168155816216912194
   PubMed Web of Science ®Google Scholar
• DelalogeSYovineATaammaAEcteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients – preliminary evidence of activityJ Clin Oncol20011951248125511230465
   PubMed Web of Science ®Google Scholar
• YovineARiofrioMBlayJYPhase II study of ecteinascidin- 743 in advanced pretreated soft tissue sarcoma patientsJ Clin Oncol200422589089914990645
   PubMed Web of Science ®Google Scholar
• Garcia-CarboneroRSupkoJGManolaJPhase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapyJ Clin Oncol20042281480149015084621
   PubMed Web of Science ®Google Scholar
• Le CesneABlayJYJudsonIPhase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trialJ Clin Oncol200523357658415659504
   PubMed Web of Science ®Google Scholar
• HuyghGClementPMDumezHEcteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patientsSarcoma200620065628217496996
   PubMedGoogle Scholar
• Garcia-CarboneroRSupkoJGMakiRGEcteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic studyJ Clin Oncol200523245484549216110008
   PubMed Web of Science ®Google Scholar
• GronchiABuiBNBonvalotSPhase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcomaAnn Oncol201223377177621642514
   PubMed Web of Science ®Google Scholar
• DemetriGDChawlaSPvon MehrenMEfficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedulesJ Clin Oncol200927254188419619652065
   PubMed Web of Science ®Google Scholar
• GomezJLázaroLLGuzmanCGonzalezAMissetJTwelvesCIdentification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743Proc Am Soc Clin Oncol200019727
   Google Scholar
• TaammaAMissetJLRiofrioMPhase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumorsJ Clin Oncol20011951256126511230466
   PubMed Web of Science ®Google Scholar
• GrossoFDileoPSanfilippoRSteroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcomaEur J Cancer200642101484149016737808
   PubMed Web of Science ®Google Scholar
• HingoraniPZhangWPiperdiSPreclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine- resistant osteosarcomaCancer Chemother Pharmacol200964473374019224214
   PubMed Web of Science ®Google Scholar
• JonesBKomarnitskyPMillerGTAmedioJWallnerBPAnticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicinAnticancer Drugs201223217318422027537
   PubMed Web of Science ®Google Scholar
• ChughRChawlaSBenjaminRHeatonJStevensJSchwartzBPhase I/II study of ZIO-201 in advanced sarcomaESMO 32nd CongressJuly 5–8, 2007Lugano, Switzerland
   Google Scholar
• ChawlaSChuaVAbbadessaGLoBueLLewisJA study of palifosfamide in combination with doxorubicin: safety and preliminary efficacyConnective Tissue Oncology Society 14th Annual MeetingNovember 13–15, 2008London, UK
   Google Scholar
• VerschraegenCFMitaMMRyanCWA phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO)J Clin Oncol201028Suppl 1510004
   Web of Science ®Google Scholar
• DuanJXJiaoHKaizermanJPotent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugsJ Med Chem20085182412242018257544
   PubMed Web of Science ®Google Scholar
• WeissGJInfanteJRChioreanEGPhase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignanciesClin Cancer Res20111792997300421415214
   PubMed Web of Science ®Google Scholar
• GanjooKNCranmerLDButrynskiJEA phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcomaOncology2011801–2505621625179
   PubMed Web of Science ®Google Scholar
• ChawlaSPAdkinsDReedDTH-302 in combination with doxorubicin in patients with first line advanced soft tissue sarcoma previously untreated with chemotherapy2011 Combined Meeting of the Connective Tissue Oncology Society and the Musculoskeletal Tumor SocietyOctober 26–29, 2011Chicago, US
   Google Scholar
• SchoffskiPRay-CoquardILCioffiAActivity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypesLancet Oncol201112111045105221937277
   PubMed Web of Science ®Google Scholar
• HeymachJVAngiogenesis and antiangiogenic approaches to sarcomasCurr Opin Oncol200113426126911429484
   PubMed Web of Science ®Google Scholar
• YoonSSSegalNHOlshenABBrennanMFSingerSCirculating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcomaAnn Oncol20041581261126615277268
   PubMed Web of Science ®Google Scholar
• SleijferSRay-CoquardIPapaiZPazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043)J Clin Oncol200927193126313219451427
   PubMed Web of Science ®Google Scholar
• van der GraafWTBlayJYChawlaSPPazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialLancet201237998291879188622595799
   PubMed Web of Science ®Google Scholar
• WeinerTMLiuETCravenRJCanceWGExpression of growth factor receptors, the focal adhesion kinase, and other tyrosine kinases in human soft tissue tumorsAnn Surg Oncol19941118277834423
   PubMed Web of Science ®Google Scholar
• FranklinWAChristisonWHColleyMMontagAGStephensJKHartCEIn situ distribution of the beta-subunit of platelet-derived growth factor receptor in nonneoplastic tissue and in soft tissue tumorsCancer Res19905019634463482169345
   PubMed Web of Science ®Google Scholar
• StrumbergDRichlyHHilgerRAPhase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumorsJ Clin Oncol200523596597215613696
   PubMed Web of Science ®Google Scholar
• MakiRGD’AdamoDRKeohanMLPhase II study of sorafenib in patients with metastatic or recurrent sarcomasJ Clin Oncol200927193133314019451436
   PubMed Web of Science ®Google Scholar
• von MehrenMRankinCGoldblumJRPhase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomasCancer2012118377077621751200
   PubMed Web of Science ®Google Scholar
• Ray-CoquardIItalianoABompasESorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF/GETO)Oncologist201217226026622285963
   PubMed Web of Science ®Google Scholar
• GounderMMLefkowitzRAKeohanMLActivity of sorafenib against desmoid tumor/deep fibromatosisClin Cancer Res201117124082409021447727
   PubMed Web of Science ®Google Scholar
• ChughRWathenJKPatelSREfficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trialClin Cancer Res201016194884489120724445
   PubMed Web of Science ®Google Scholar
• GeorgeSBlayJYCasaliPGClinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failureEur J Cancer200945111959196819282169
   PubMed Web of Science ®Google Scholar
• GeorgeSMerriamPMakiRGMulticenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomasJ Clin Oncol200927193154316019451429
   PubMed Web of Science ®Google Scholar
• StacchiottiSNegriTLibertiniMSunitinib malate in solitary fibrous tumor (SFT)Ann Oncol Epub June 17, 2012
   Web of Science ®Google Scholar
• HensleyMLSillMWScribnerDRJrSunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II studyGynecol Oncol2009115346046519811811
   PubMed Web of Science ®Google Scholar
• SchwartzGKRatainMJUndeviaSDBrivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): biomarker and subset results of a phase II randomized discontinuation triaJ Clin Oncol201129 Suppl10000
   Web of Science ®Google Scholar
• GardnerKLeahyMBarquinEActivity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcomaJ Clin Oncol200927 Suppl 1510523
   Google Scholar
• KummarSMonksAIvySPAn evaluation of cediranib as a new agent for alveolar soft part sarcoma (ASPS)J Clin Oncol201129 Suppl10001
   Google Scholar
• AgulnikMVon MehrenMJovanovicBBrocksteinBBenjaminRSEvensAMAn open-label multicenter phase II study of bevacizumab for the treatment of angiosarcomaJ Clin Oncol200927 Suppl 1510522
   Google Scholar
• FullerCKCharlsonJADankleSKRussellTJDramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapyJ Am Acad Dermatol2010634e83e8420846560
   PubMedGoogle Scholar
• RosenAThimonSTernantDMachetMCPaintaudGMachetLPartial response to bevacizumab of an extensive cutaneous angiosarcoma of the faceBr J Dermatol2010163122522720394623
   PubMed Web of Science ®Google Scholar
• D’AdamoDRAndersonSEAlbrittonKPhase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomasJ Clin Oncol200523287135714216192597
   PubMed Web of Science ®Google Scholar
• VerschraegenCFArias-PulidoHLeeSJPhase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimenAnn Oncol201223378579021746804
   PubMed Web of Science ®Google Scholar
• ParkMSPatelSRLudwigJAActivity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumorCancer2011117214939494721480200
   PubMed Web of Science ®Google Scholar
• ChoiHCharnsangavejCFariaSCCorrelation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteriaJ Clin Oncol200725131753175917470865
   PubMed Web of Science ®Google Scholar
• RikhofBde JongSSuurmeijerAJMeijerCvan der GraafWTThe insulin-like growth factor system and sarcomasJ Pathol2009217446948219148905
   PubMed Web of Science ®Google Scholar
• PrieurATirodeFCohenPDelattreOEWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3Mol Cell Biol200424167275728315282325
   PubMed Web of Science ®Google Scholar
• MalempatiSWeigelBIngleAMPhase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children’s Oncology GroupJ Clin Oncol201230325626222184397
   PubMed Web of Science ®Google Scholar
• TolcherAWSarantopoulosJPatnaikAPhase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1J Clin Oncol200927345800580719786654
   PubMed Web of Science ®Google Scholar
• SchoffskiPAdkinsDBlayJPhase II trial of anti-IGF-IR antibody cixutumumab in patients with advanced or metastatic soft-tissue sarcoma and Ewing family of tumorsJ Clin Oncol201129 Suppl 1510004
   Web of Science ®Google Scholar
• KurmashevaRTDudkinLBillupsCDebelenkoLVMortonCLHoughtonPJThe insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcomaCancer Res200969197662767119789339
   PubMed Web of Science ®Google Scholar
• NaingALoRussoPFuSInsulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing’s sarcoma family tumorsClin Cancer Res20121892625263122465830
   PubMed Web of Science ®Google Scholar
• SchwartzGK TWQinLA phase II multicenter study of the IGF-1 receptor antibody cixutumumab (A12) and the mTOR inhibitor temsirolimus (TEM) in patients (pts) with refractory IGF-1R positive (+) and negative (−) bone and soft tissue sarcomas (STS)J Clin Oncol201230 Suppl10003
   Google Scholar
• ChughRGriffithKABrocksteinBUndeviaSDStadlerWMSchuetzeSPhase I study of doxorubicin (D) plus anti-insulin-like growth factor 1 receptor (IGF-1R) antibody cixutumumab (IMC-A12) in advanced soft tissue sarcoma (STS)J Clin Oncol201230 Suppl10028
   Google Scholar
• SchmelzleTHallMNTOR, a central controller of cell growthCell2000103225326211057898
   PubMed Web of Science ®Google Scholar
• BrownEJSchreiberSLA signaling pathway to translational controlCell19968645175208752206
   PubMed Web of Science ®Google Scholar
• ChawlaSPStaddonAPBakerLHPhase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomasJ Clin Oncol2012301788422067397
   PubMed Web of Science ®Google Scholar
• OkunoSBaileyHMahoneyMRA phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C)Cancer2011117153468347521287536
   PubMed Web of Science ®Google Scholar
• QuekRWangQMorganJACombination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumorsClin Cancer Res201117487187921177764
   PubMed Web of Science ®Google Scholar
• SchuetzeSMBakerLHMakiRGSirolimus reduced tumor-related morbidity and resulted in biochemical and radiographic response in patients with progressive sarcomaJ Clin Oncol200624Suppl 18 Abstr 9503
   Web of Science ®Google Scholar
• SchuetzeSZhaoLChughRResults of a phase II trial of sirolimus (S) and cyclophosphamide (C) in advanced sarcomaJ Clin Oncol201129 Suppl10003
   Web of Science ®Google Scholar
• WagnerAJMalinowska-KolodziejIMorganJAClinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumorsJ Clin Oncol201028583584020048174
   PubMed Web of Science ®Google Scholar
• ItalianoADelcambreCHosteinITreatment with the mTOR inhibitor temsirolimus in patients with malignant PEComaAnn Oncol20102151135113720215136
   PubMed Web of Science ®Google Scholar
• KuhnenCMuehlbergerTHonselMTolnayESteinauHUMullerKMImpact of c-Met expression on angiogenesis in soft tissue sarcomas: correlation to microvessel-densityJ Cancer Res Clin Oncol2003129741542214605882
   PubMed Web of Science ®Google Scholar
• OdaYSakamotoASaitoTKinukawaNIwamotoYTsuneyoshiMExpression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-MET correlates with poor prognosis in synovial sarcomaHum Pathol200031218519210685632
   PubMed Web of Science ®Google Scholar
• KurzrockRShermanSIBallDWActivity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancerJ Clin Oncol201129192660266621606412
   PubMed Web of Science ®Google Scholar
• ButrynskiJED’AdamoDRHornickJLCrizotinib in ALK-rearranged inflammatory myofibroblastic tumorN Engl J Med2010363181727173320979472
   PubMed Web of Science ®Google Scholar
• SingerSSocciNDAmbrosiniGGene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcomaCancer Res200767146626663617638873
   PubMed Web of Science ®Google Scholar